Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED

Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

NCT00253669 · View on ClinicalTrials.gov ↗

Study Summary

RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas. PURPOSE: This clinical trial is studying risk factors for developing blood clots in patients who are undergoing cancer treatment for newly diagnosed gliomas.

Interventions

  • OTHER laboratory biomarker analysis
  • OTHER physiologic testing
  • PROCEDURE management of therapy complications

Study Locations (9)

Alabama

  • Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham — Birmingham

Florida

  • H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa

Georgia

  • Winship Cancer Institute of Emory University — Atlanta

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore

Massachusetts

  • Massachusetts General Hospital — Boston

Michigan

  • Josephine Ford Cancer Center at Henry Ford Hospital — Detroit

North Carolina

  • Wake Forest University Comprehensive Cancer Center — Winston-Salem

Ohio

  • Cleveland Clinic Taussig Cancer Center — Cleveland

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2005-04
Est. Completion 2009-08

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00253669

The ClinicalTrials.gov registry entry for NCT00253669 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 311 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Brain and Central Nervous System Tumors appearing as the primary indexed condition, and to 3 interventions — of which laboratory biomarker analysis is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT00253669 reports 9 study locations spanning 9 distinct geographic areas — top geographies include Alabama, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT00253669 about?

NCT00253669 is a clinical study titled "Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas". RATIONALE: Patients with gliomas may be at risk for developing blood clots. Learning about the risk factors for developing blood clots may help doctors plan better treatment for gliomas. PURPOSE: This clinical trial is studying risk factors for developing blood clots in patients who are undergoing ...

What is the current status of trial NCT00253669?

This trial is currently completed. The enrollment target is 110 participants. The study started on 2005-04. Estimated completion is 2009-08.

What conditions does trial NCT00253669 study?

This clinical trial studies the following conditions: Brain and Central Nervous System Tumors, Thromboembolism. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT00253669?

The interventions under investigation include: laboratory biomarker analysis (OTHER), physiologic testing (OTHER), management of therapy complications (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT00253669?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 311 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT00253669 being conducted?

This trial has 9 study locations across Alabama, Florida, Georgia, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial